文献速递骨软组织肉瘤与黑色素瘤

局限性软组织肉瘤的(新)辅助治疗:尚未解决的难题

(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair.
PubMed 文献 · Eur J Cancer · 2016-11-17

本文是一篇综述,聚焦局限性软组织肉瘤(STS)的(新)辅助治疗。作者指出手术仍是局限性STS的治疗基石,而辅助与新辅助治疗的地位仍存诸多不确定性;现有对照证据常互相矛盾,不足以使化疗(CT)成为标准实践,目前不存在共同认可的策略;最大疑问在于前瞻性识别最可能从(新)辅助治疗获益的患者亚组。

要点

  • 手术仍是局限性软组织肉瘤的治疗基石
  • 现有对照证据常互相矛盾,不足以使化疗成为标准实践
  • 目前不存在共同认可的(新)辅助治疗策略

核心结论

  • 作者认为,现有对照证据常互相矛盾且不足以使化疗成为标准实践,目前不存在共同认可的(新)辅助治疗策略。
  • 作者认为最大的问题在于前瞻性识别最可能从(新)辅助治疗获益的患者亚组。
  • 鉴于对不同肉瘤亚型生物学与敏感性的认识不断增加,组织学在围手术期治疗选择中的价值是讨论中最受关注的话题之一。
  • 作者指出新一代新辅助试验已规划并正在进行中。
  • 本综述旨在重新唤起对局限性STS(新)辅助化疗这一长期话题的兴趣,更新其在肉瘤管理中的作用并强调未来方向。

研究设计与样本

  • 综述,旨在更新(新)辅助化疗在局限性软组织肉瘤管理中的作用。
  • 文章检索范围与纳入文献情况原文未报告。

主要发现

  • 软组织肉瘤(STS)是罕见且异质的肿瘤。
  • 从疾病管理伊始就正确界定STS,对指导诊断与影像检查、帮助确立预后并据此制定治疗策略至关重要。
  • 过去数年已付出许多努力以识别可预测疾病行为的特征,并丰富针对晚期疾病的治疗手段,晚期疾病预后仍差。
  • 手术仍是局限性STS的治疗里程碑,而辅助与新辅助治疗的作用仍存许多不确定性。
  • 有一些对照证据,但常互相矛盾且不足以使化疗(CT)成为标准实践,目前不存在共同且共享的策略。

关键数值与推荐

  • 原文未报告具体标准与数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Soft tissue sarcomas (STS) are rare and heterogeneous tumours. A correct definition of STS is imperative from the very beginning of disease management, to guide the diagnostic and imaging work-up, and help to establish the prognosis on which the therapeutic strategy will be based. Over the last few years, many efforts have been made to identify characteristics that could predict disease behaviour and to enrich the therapeutic armamentarium against the advanced disease, that is still characterised by poor prognosis. Surgery remains the milestone of treatment for localised STS, whereas many uncertainties regarding the role of adjuvant and neoadjuvant treatment persist. Some controlled evidence is available, but often conflicting and insufficient to make chemotherapy (CT) a standard practice and, currently, a common and shared strategy does not exist. The biggest question concerns the prospective identification of the subgroup of patients who would benefit the most from (neo)adjuvant therapies. In light of the growing understanding of different biologies and sensitivities of the various sarcoma subtypes, the value of histology in the selection of peri-operative treatments is one of the most intriguing topics under discussion. In this perspective, a new generation of neoadjuvant trials have been planned and are currently ongoing. The aim of this review was to rekindle interest in the long-standing topic of (neo)adjuvant CT in localised STS, providing an update on its role in sarcomas' management and highlighting future directions and consequential factors needed to further improve outcomes in this disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saponara M, Stacchiotti S, Casali PG, et al. (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. Eur J Cancer. 2016. PMID: 27866094. doi:10.1016/j.ejca.2016.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。